Tag: legislation

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.^3,4 A final decision on the approval in the European Union is expected in the coming months.

MONTRÉAL, June 19, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Company” or “Premier Health”), a leading Canadian health tech company, today announced that its Board of Directors (the “Board”) has initiated a formal strategic review process to identify, review and evaluate a broad range of potential strategic alternatives available to it with a view to continuing to enhance shareholder value.

MONTREAL, June 19, 2025 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Company”) (TSX: BLX) today announced that the Chair of its Board of Directors, Mr. Alain Rhéaume, has informed the Board that he will step down from his position once a successor has been appointed by the directors, no later than December of this year.

MONTREAL, June 18, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is undertaking a rights offering (the “Rights Offering”). The Company will be offering a maximum of 353,409,888 rights (the “Rights”) to holders (the “Shareholders”) of its common shares (the “Shares”) as at the close of business on the record date of June 25, 2025 (the “Record Date”) on the basis of one (1) Right for each one (1) Share held. Each one (1) Right will entitle the holder to subscribe for one Share (each, a “Rights Share”) at the subscription price of $0.0825 per Rights Share.

CALGARY, Alberta, June 18, 2025 (GLOBE NEWSWIRE) -- Condor Energies Inc. (“Condor” or the “Company”) (TSX: CDR), a Canadian based, internationally focused energy transition company with active operations in Central Asia is pleased to provide an update.